BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2896496)

  • 1. Genes encoding drug-metabolizing enzymes: possible role in human disease.
    Nebert DW
    Basic Life Sci; 1988; 43():45-64. PubMed ID: 2896496
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular genetics of the debrisoquin-sparteine polymorphism.
    Gonzalez FJ; Meyer UA
    Clin Pharmacol Ther; 1991 Sep; 50(3):233-8. PubMed ID: 1680592
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacogenetics: Part I.
    Gibaldi M
    Ann Pharmacother; 1992 Jan; 26(1):121-6. PubMed ID: 1606333
    [No Abstract]   [Full Text] [Related]  

  • 4. [Genetic polymorphism of the hepatic metabolism of drugs].
    Larrey D; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1985; 9(6-7):522-31. PubMed ID: 3926587
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenetic polymorphism of drug metabolism.
    Paxton JW
    N Z Med J; 1984 Aug; 97(762):567-9. PubMed ID: 6591031
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacogenetic perspectives: genes, drugs and disease.
    Vesell ES
    Hepatology; 1984; 4(5):959-65. PubMed ID: 6434393
    [No Abstract]   [Full Text] [Related]  

  • 7. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
    Skoda RC; Gonzalez FJ; Demierre A; Meyer UA
    Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics: Part II.
    Gibaldi M
    Ann Pharmacother; 1992 Feb; 26(2):255-61. PubMed ID: 1554942
    [No Abstract]   [Full Text] [Related]  

  • 9. Current cellular assays for measuring clinical drug metabolizing capacity--impact of new molecular biologic techniques.
    Kouri RE; McLemore T; Jaiswal AK; Nebert DW
    Prog Clin Biol Res; 1986; 214():453-69. PubMed ID: 3523516
    [No Abstract]   [Full Text] [Related]  

  • 10. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human P-450 genes: evolution, regulation and possible role in carcinogenesis.
    Nebert DW; Jaiswal AK; Meyer UA; Gonzalez FJ
    Biochem Soc Trans; 1987 Aug; 15(4):586-9. PubMed ID: 3678581
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.
    van Schaik RH
    Invest New Drugs; 2005 Dec; 23(6):513-22. PubMed ID: 16267627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Human biodiversity and its effects on the pharmacological variability: CYP2D6 and NAT2 enzymes in Amerind populations of Panama, Colombia and Costa Rica].
    Jorge LF; Arias TD
    Rev Med Panama; 1995 Sep; 20(3):98-107. PubMed ID: 8668827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of genetics and drug metabolism in human cancer risk.
    Nebert DW
    Mutat Res; 1991 Apr; 247(2):267-81. PubMed ID: 2011144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacogenetics and its clinical implications: N-acetylation polymorphism.
    Horai Y; Ishizaki T
    Ration Drug Ther; 1987 Oct; 21(10):1-7. PubMed ID: 3326026
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacogenetics and its importance in the clinical].
    Lares-Asseff I; Trujillo-Jiménez F
    Gac Med Mex; 2001; 137(3):227-36. PubMed ID: 11432091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping genes encoding drug-metabolizing enzymes in recombinant inbred mice.
    Miles JS; Moss JE; Taylor BA; Burchell B; Wolf CR
    Genomics; 1991 Oct; 11(2):309-16. PubMed ID: 1685137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
    Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
    Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.